Submitted: 10 Jun 2019
Accepted: 09 Aug 2019
ePublished: 19 Oct 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2020;9(2): e14.
doi: 10.34172/npj.2020.14

Scopus ID: 85086044411
  Abstract View: 867
  PDF Download: 276


Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes

Tarun Kumar Jeloka 1 * ORCID logo, Datta Jayanta 2, Suresh Babu Vallamkonda 3, Sujeet Narayan Charugulla 4, Gupta Namita 4

1 Department of Nephrology and Kidney Transplant, Aditya Birla Memorial Hospital Pune, India
2 Department of Nephrology and Renal Transplant Surgery, Columbia Asia Hospital, Kolkata, India
3 Department of Nephrology, Yashoda Hospital, Hyderabad, India
4 Department of Medical Affairs, Dr Reddy’s Laboratories, Hyderabad, India
*Corresponding author: Jeloka Tarun K, Email: tjeloka@yahoo.com


Individuals with chronic renal failure in stage three and after demonstrate anemia as a frequent complication. Although target hemoglobin levels remain debatable in pre-dialysis and dialysis patients, correction of anemia with erythropoiesis-stimulating agents (ESAs) has resulted in reduced need for blood transfusions, improved survival and enhanced overall quality of life. Owing to longer half-life and greater biological activity, darbepoetin alfa can maintain stable hemoglobin levels at extended dosing intervals. It is also economical and convenient with no compromise in efficacy. Studies have shown similar dose requirements for both intravenous versus subcutaneous darbepoetin in pre-dialysis and dialysis patients. This review article focuses on clinical outcomes of darbepoetin including the achieved hemoglobin target, maintenance of hemoglobin levels, all-cause mortality, cardiovascular events, additional blood transfusion, quality of life, and economic outcomes in patients with chronic kidney disease (CKD). This review also outlines the risk associated with darbepoetin administration and changes in guidelines recommendation for improving its use.
Keywords: Anemia, Blood transfusions, Chronic kidney disease, Darbepoetin alfa, Erythropoiesis stimulating agents

Implication for health policy/practice/research/medical education: The main advantages of darbepoetin are efficacious anemia correction and reduction of blood transfusions.

Please cite this paper as: Jeloka TK, Jayanta D, Vallamkonda SB, Charugulla SN, Namita G. Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes. J Nephropharmacol. 2020;9(2):e14. DOI: 10.34172/npj.2020.14.

First Name
Last Name
Email Address
Security code

Abstract View: 867

Your browser does not support the canvas element.

PDF Download: 276

Your browser does not support the canvas element.